• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外源性抗原呈递的转录组学指标与适应性免疫和局部雌激素受体阴性乳腺癌局部区域复发之间的关联:多机构数据集的回顾性研究

Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets.

作者信息

Robinson Timothy J, Liveringhouse Casey L, Wilson Christopher, Friedman Sam, Nakashima Justyn, Mills Matthew N, Purcell Jacob D, Figura Nicholas B, Dongliang Du, Thapa Ram, Welsh Eric, Ahmed Kamran A, Grass G Daniel, Fridley Brooke L, Diaz Roberto

机构信息

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA.

Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

出版信息

Breast Cancer Res. 2025 May 13;27(1):77. doi: 10.1186/s13058-025-01987-x.

DOI:10.1186/s13058-025-01987-x
PMID:40361136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12070507/
Abstract

BACKGROUND

Transcriptomic features of breast cancer locoregional recurrence (LRR) remain poorly understood. We therefore sought to investigate transcriptomic features associated with LRR in newly diagnosed invasive breast tumors from our institutional dataset.

METHODS

Transcriptomic profiling was performed on 632 tumors from consecutive patients treated within our health system for newly diagnosed non-metastatic breast cancer. Univariable Cox models identified genes whose expression was associated with LRR (q-value < 0.05). Up-regulated (UR) genes were defined as hazard ratio (HR) > 1 and down-regulated (DR) genes were defined as HR < 1. Gene set enrichment analyses were performed for UR and DR gene sets and validated within two external cohorts of ER- tumors.

RESULTS

With a median follow-up of 7.6 years, we observed 38 LRRs: 28/481 (5.8%) in ER + and 10/151 (6.6%) in ER-. There were 43 UR and 7 DR genes associated with LRR in ER + tumors, while 417 UR and 1150 DR genes were associated with LRR in ER- tumors. UR genes in ER + tumors were enriched for roles in cell proliferation (q < 0.05). In contrast, LRR in ER- tumors was most strongly associated with DR genes enriched for MHC-II-mediated antigen presentation and T cell activation (q < 0.05). In external cohorts of ER- tumors, 97 significant DR genes (p < 0.05) were enriched for 18 pathways, including 5 pathways involved in MHC-II signaling, antigen presentation and T-cell activation.

CONCLUSIONS

Transcriptomic patterns associated with LRR appear distinct between ER + and ER- tumors. In ER + tumors, LRR appears predominantly associated with proliferation, whereas ER- LRR suggests a robust pattern of suppressed antigen presentation via MHC-II.

摘要

背景

乳腺癌局部区域复发(LRR)的转录组特征仍了解甚少。因此,我们试图从我们机构的数据集中研究新诊断的浸润性乳腺肿瘤中与LRR相关的转录组特征。

方法

对在我们医疗系统中接受治疗的连续患者的632例新诊断为非转移性乳腺癌的肿瘤进行转录组分析。单变量Cox模型确定其表达与LRR相关的基因(q值<0.05)。上调(UR)基因定义为风险比(HR)>1,下调(DR)基因定义为HR<1。对UR和DR基因集进行基因集富集分析,并在两个ER-肿瘤外部队列中进行验证。

结果

中位随访7.6年,我们观察到38例LRR:ER+肿瘤中28/481例(5.8%),ER-肿瘤中10/151例(6.6%)。ER+肿瘤中有43个UR基因和7个DR基因与LRR相关,而ER-肿瘤中有417个UR基因和1150个DR基因与LRR相关。ER+肿瘤中的UR基因在细胞增殖中富集(q<0.05)。相比之下,ER-肿瘤中的LRR与DR基因最密切相关,这些基因在MHC-II介导的抗原呈递和T细胞活化中富集(q<0.05)。在ER-肿瘤的外部队列中,97个显著的DR基因(p<0.05)在18条通路中富集,包括5条参与MHC-II信号传导、抗原呈递和T细胞活化的通路。

结论

ER+和ER-肿瘤中与LRR相关的转录组模式似乎不同。在ER+肿瘤中,LRR似乎主要与增殖相关,而ER- LRR提示通过MHC-II抑制抗原呈递的强烈模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/f626bac240d6/13058_2025_1987_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/7df93fc28066/13058_2025_1987_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/b8f8d5064230/13058_2025_1987_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/02254cb1feaf/13058_2025_1987_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/f626bac240d6/13058_2025_1987_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/7df93fc28066/13058_2025_1987_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/b8f8d5064230/13058_2025_1987_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/02254cb1feaf/13058_2025_1987_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/12070507/f626bac240d6/13058_2025_1987_Fig4_HTML.jpg

相似文献

1
Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets.外源性抗原呈递的转录组学指标与适应性免疫和局部雌激素受体阴性乳腺癌局部区域复发之间的关联:多机构数据集的回顾性研究
Breast Cancer Res. 2025 May 13;27(1):77. doi: 10.1186/s13058-025-01987-x.
2
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.21 基因复发评分与淋巴结阴性、雌激素受体阳性乳腺癌的局部区域复发。
Breast Cancer Res Treat. 2017 Nov;166(1):69-76. doi: 10.1007/s10549-017-4381-7. Epub 2017 Jul 12.
3
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.乳腺癌 21 基因复发评分低于 18:大系列临床随访的局部区域复发率。
BMC Cancer. 2018 Jan 6;18(1):42. doi: 10.1186/s12885-017-3985-y.
4
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.21基因复发评分与接受化疗-内分泌治疗的淋巴结阳性/雌激素受体阳性乳腺癌的局部区域复发
J Natl Cancer Inst. 2017 Jan 25;109(4). doi: 10.1093/jnci/djw259. Print 2017 Jan.
5
BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.BRAF/MEK 通路与 ER 依赖性乳腺癌相关,并改善基于 ER 状态的癌症复发预测。
Clin Breast Cancer. 2020 Feb;20(1):41-50.e8. doi: 10.1016/j.clbc.2019.08.005. Epub 2019 Aug 29.
6
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.雌激素受体低表达和阴性早期乳腺癌的免疫及基因表达谱分析
J Natl Cancer Inst. 2024 Dec 1;116(12):1914-1927. doi: 10.1093/jnci/djae178.
7
The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.新诊断乳腺癌中生物学亚型与局部区域复发的相关性。
Breast Cancer Res Treat. 2010 Nov;124(1):187-94. doi: 10.1007/s10549-010-1135-1. Epub 2010 Sep 3.
8
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.21 基因检测复发评分与淋巴结阳性乳腺癌患者局部区域复发率的相关性。
JAMA Oncol. 2020 Apr 1;6(4):505-511. doi: 10.1001/jamaoncol.2019.5559.
9
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.21 基因复发评分检测与淋巴结阴性、雌激素受体阳性乳腺癌局部区域复发风险的相关性:来自 NSABP B-14 和 NSABP B-20 的结果。
J Clin Oncol. 2010 Apr 1;28(10):1677-83. doi: 10.1200/JCO.2009.23.7610. Epub 2010 Jan 11.
10
Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?行保乳术治疗的 pT1-2N0 乳腺癌女性,生物学亚型是否与局部区域复发风险相关?
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):57-64. doi: 10.1016/j.ijrobp.2013.09.024. Epub 2013 Oct 22.

本文引用的文献

1
The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy.放射敏感性指数基因特征可识别与对放射治疗敏感性相关的不同肿瘤免疫微环境特征。
Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):635-647. doi: 10.1016/j.ijrobp.2022.03.006. Epub 2022 Mar 12.
2
A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences.可能预示乳腺癌放射治疗后早期与晚期复发的特征,有助于了解早期侵袭性复发的生物学特征。
Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):686-696. doi: 10.1016/j.ijrobp.2020.05.015. Epub 2020 May 17.
3
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.
优化放疗以增强乳腺癌的全身免疫反应:对乳腺癌放疗肿瘤学家的重要评价。
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):227-241. doi: 10.1016/j.ijrobp.2020.05.011. Epub 2020 May 14.
4
HER2-Low Breast Cancer: Pathological and Clinical Landscape.人表皮生长因子受体2低表达乳腺癌:病理及临床概况
J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24.
5
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.帕博利珠单抗联合化疗作为高危早期三阴性乳腺癌的新辅助治疗:来自 1b 期开放标签、多队列 KEYNOTE-173 研究的结果。
Ann Oncol. 2020 May;31(5):569-581. doi: 10.1016/j.annonc.2020.01.072. Epub 2020 Feb 14.
6
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
7
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.帕博利珠单抗联合新辅助化疗对早期乳腺癌患者病理完全缓解的影响:正在进行的 2 期适应性随机 I-SPY2 试验分析。
JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650.
8
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.21 基因检测复发评分与淋巴结阳性乳腺癌患者局部区域复发率的相关性。
JAMA Oncol. 2020 Apr 1;6(4):505-511. doi: 10.1001/jamaoncol.2019.5559.
9
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.一项评估帕博利珠单抗联合放疗治疗转移性三阴性乳腺癌患者的疗效和安全性的 2 期临床试验。
Cancer. 2020 Feb 15;126(4):850-860. doi: 10.1002/cncr.32599. Epub 2019 Nov 20.
10
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.鉴定具有潜在治疗意义的三阴性乳腺癌三种亚型。
Breast Cancer Res. 2019 May 17;21(1):65. doi: 10.1186/s13058-019-1148-6.